See V-LTY LIBERTY BIOPHARMA TO ACQUIRE CLOUD MEDICAL GROUP
Liberty Biopharma Inc. has received conditional approval from the TSX Venture Exchange of the proposed acquisition and share exchange transaction with Cloud Medical Group Inc. (CMGI).
CMGI is a health care technology company founded in 2014 with exclusive licensing agreements with Seven Stars Medical Inc. Seven Stars Medical is focused on the development of a medical platform as a service (MPaaS), which is a business that has revenue, marketing and operational interests in a network of high-end medical and diagnostic clinics for regenerative medicine, stem cell therapy, oncology, immunotherapy, virtual reality consultations, and preventative medicine and treatment decision making utilizing big data cloud from Tencent.
Seven Stars Medical was founded by Bruno Wu, the chairman and chief executive officer of Seven Stars Cloud Group Inc. (SSC), the global leading next-generation artificial intelligence and blockchain-powered financial technology company that offers supply chain and digital finance solutions for the energy and commodities industries. Mr. Wu is also the founder, co-chairman and chief executive officer of Sun Seven Stars Media Group Ltd., one of the largest and most diversified private media and investment companies in China.
As part of the CMGI acquisition, Liberty Biopharma will work with the Seven Stars medical clinical team for access to MPaaS partner health clinics in China, Macau and Hong Kong for the implementation of its proprietary adipose stem cell isolation technology for anti-aging, osteoarthritis and medical aesthetics. Effective immediately, Dr. Michael T. McNamara will be appointed to Liberty Biopharma's medical advisory committee.
Dr. McNamara is the co-chief executive officer and chief medical officer of Seven Stars Medical. Dr. McNamara leads a unique specialty of preventive health practice using the most sophisticated modalities of diagnostic imaging and blood analysis. He founded the first hospital-based MRI (Magnetic resonance imaging) department in Europe in 1986 at the Princess Grace Hospital in Monaco. Dr. McNamara developed the world's first preventive total body scanning program for the early detection of cardiovascular and autoimmune diseases, cancer, and degenerative abnormalities. He has prior experience implementing regenerative medical treatment programs. He has served on the medical advisory boards of General Electric Medical Systems, Bristol-Meyers Squibb, Nycomed Laboratories, Bracco Diagnostics, Akloma Biosciences, the Angiogenesis Foundation and uBiome Inc. Dr. McNamara received his MD at the University of Michigan in Ann Arbor, United States.
CMGI's MPaaS system will be integrating virtual reality, artificial intelligence, cloud-based mobile delivery, blockchain financial fulfilment and big data informatics from Seven Stars Cloud Group for a royalty of 2 per cent of revenues derived from the MPaaS system. CMGI also has a 49-per-cent beneficial interest in Medisun Healthcare (China) Ltd., a Hong Kong cell therapy and marketing joint venture in which the 51-per-cent joint venture partner, Medisun Holdings Ltd., signed a master health care agreement in 2015 with Mayo Clinic to carry out a multifaceted, innovative collaboration advancing health care delivery and establishing a jointly affiliated hospital network system under the Mayo Clinic care network in Hong Kong and China, offering telemedicine, training programs in hospital management, and specialist technologies in regenerative medicine and oncology.
CMGI also has co-operation arrangements with: (i) Meinian Onehealth Healthcare (Group) Co. Ltd. to expand MPaaS and marketing services to over 300 health clinics in China; (ii) Centre Testing International Group Co. Ltd. to expand the marketing of medical services and Lumenis cosmetic laser applications in China; and (iii) LDG Labor Deutschland (known as Laboratories Dr. Gansauge) for the marketing and delivery of oncological dendritic cell therapy and cancer vaccines in China, Macau and Hong Kong with over 6,000 patients treated globally (U.S. Food and Drug Administration and European Medicines Agency approved). CMGI also has a 70-per-cent beneficial interest in Guiyang, China -- a flagship demonstration-sharing clinic for executive health in preventative medicine, gene sequencing, gene detection and cell therapy, medical imaging and big data informatics with segregated cash reserves of $3.8-million.
The CMGI vendors have direct access to marketing influencers through key media personalities that have access to over 40 million Weibo users, one million WeChat users, and other social media groups and apps, along with full media coverage on major media platforms such as Tencent, iQiui, Netease, Yizhibo and Huajia.